Skip to content

PCI Alternative Using Sustained Exercise

PCI Alternative Using Sustained Exercise (PAUSE)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03520400
Acronym
PAUSE
Enrollment
51
Registered
2018-05-09
Start date
2012-10-01
Completion date
2019-09-30
Last updated
2024-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Cardiovascular Disease, Percutaneous Intervention, coronary artery disease, exercise therapy

Brief summary

Cardiovascular disease remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Most of these deaths are due to coronary artery disease (CAD). The most common treatment for CAD is revascularization, an invasive procedure which usually involves placing a stent inside an artery that is diseased. However, exercise training is often overlooked because clinicians tend to focus on repairing the coronary circulation and the potential need for revascularization. Studies have shown that exercise training can be effective for patients with CAD and that it saves costs. In this study, invasive revascularization will be compared to a structured program of exercise training over one year. Comparisons will be made between groups for symptoms, coronary artery size and function using PET/CTA, and health care cost utilization.

Detailed description

Despite advances in treatment options for cardiovascular disease (CVD), this condition remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Percutaneous coronary intervention (PCI) is the treatment most often used in patients with various manifestations of coronary artery disease (CAD). While it is commonly assumed that PCI also reduces mortality, randomized trials have shown that PCI has no effect on mortality except in patients being treated for acute myocardial infarction. Over the last decade, the use of PCI has increased exponentially; between 1996 and 2007, the number of PCIs performed in the US has increased more than 4-fold, from approximately 300,000 to more than 1.3 million yearly. During this time, PCI has accounted for 10% of the overall increase in Medicare expenditures. In light of the extraordinary increase in the use of this technology in recent years, questions have been raised regarding the cost-effectiveness of PCI, the extent to which PCI is overused, and whether selected patients may benefit from optimal medical therapy in lieu of PCI. Cost analyses have suggested that the current rate of increase in PCI with DES is unsustainable for the U.S. healthcare system. Given the costs associated with PCI, there have been recent efforts to compare outcomes and effectiveness of PCI against non-invasive therapy. There is a need to evaluate more judicious use of PCI, and to consider less costly interventions for at least some of the \>1.3 million patients in the U.S. who undergo this procedure. Lifestyle intervention, including exercise training, is one option that has been shown to result in reduced symptoms, better exercise tolerance, improved quality of life and lower mortality. A growing body of data has demonstrated that exercise intervention improves coronary anatomy and lessens ischemia through enhanced endothelial function. While a significant proportion of health care expenditures are devoted to PCI and other invasive interventions for CVD, few health care resources are directed toward primary or secondary prevention. Recent studies have demonstrated that programs of cardiac rehabilitation, with and without implementation of intensive risk reduction, are cost effective. In part because of the financial interests associated with PCI, exercise and lifestyle intervention is rarely considered as a clinical treatment option in PCI candidates. A gap exists between the standard clinical treatment for CAD and the potential for non-invasive, less expensive and potentially more effective treatments for these patients. Previous efforts to quantify the effects of exercise and lifestyle intervention on coronary artery perfusion and anatomy have been limited to standard angiography. In recent years, improved technologies for imaging coronary perfusion and anatomy have been developed, which could provide important insights into the effects of exercise training on the heart. These include the combination of positron emission tomography and ultra-fast computed tomography angiography (CTA), commonly termed PET/CTA. PET provides information on the functional significance of anatomic stenoses by measuring myocardial blood flow and myocardial perfusion reserve. PET can also be used to evaluate coronary endothelial function by measurements of changes in myocardial blood flow in response to physical stimuli (i.e., cold pressor testing). The combination of CTA with PET also allows for improved attenuation correction. CTA, on the other hand, can noninvasively image the coronary arteries to determine the severity of stenosis and the amount of calcified and noncalcified plaque burden. The investigators have termed the current proposal PCI Alternative Using Sustained Exercise (PAUSE) to reflect the potential for exercise training and lifestyle intervention as alternative therapies in selected PCI candidates. Primary aim: To determine whether subjects with lesions amenable to PCI randomized to a 1 year exercise program and lifestyle intervention have greater improvement in coronary perfusion and function than those randomized to PCI. Secondary analyses: The investigators will compare exercise test responses, health care costs, quality of life, and clinical outcomes between groups.

Interventions

BEHAVIORALExercise Therapy

Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Stable patients who have lesions appropriate for PCI based on American Heart Association/American College of Cardiology criteria will be considered for the study. * Only patients with a good prognosis (annual mortality \<2% based on VA multivariate scores (57, 58) will be considered.

Exclusion criteria

* Patients with left main disease or proximal LAD disease, or: * Unstable angina * A history of left ventricular dysfunction (EF 30%) * Pacemakers * Atrial fibrillation * Myocardial infarction within the last 3 months * Diabetes * Orthopedic problems interfering with the ability to exercise regularly

Design outcomes

Primary

MeasureTime frameDescription
Myocardial Perfusion Reservebaseline and 1 yearMeasurement of myocardial blood flow has only been analyzed at baseline at this time. Intravenous 13NH3 will be used as the flow tracer and serial imaging with PET will be performed. Measurements will be performed at baseline, and after pharmacologic stress with dipyridamole. Myocardial blood flow at rest and following dipyridamole infusion will be expressed as ml flow/100 g/min. The myocardial perfusion reserve will be calculated as the ratio of the myocardial blood flow during stress (e.g. after dipyridamole) and the myocardial blood flow at rest. Commercially available software (Emory tool box) will be used to quantitatively analyze PET myocardial perfusion images.

Secondary

MeasureTime frameDescription
Peak VO2baseline and after 1 yearPeak VO2 will be determined at baseline and 1 year on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses.

Countries

United States

Participant flow

Participants by arm

ArmCount
Exercise Intervention Group
Group receives one year of exercise and lifestyle intervention Exercise Therapy: Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
22
PCI Group (Usual Care)
Group receives standard clinical care with no intervention
7
Total29

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision157

Baseline characteristics

CharacteristicPCI Group (Usual Care)TotalExercise Intervention Group
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
5 Participants20 Participants15 Participants
Age, Categorical
Between 18 and 65 years
2 Participants9 Participants7 Participants
Age, Continuous69.0 years
STANDARD_DEVIATION 7.3
67.4 years
STANDARD_DEVIATION 4.5
66.6 years
STANDARD_DEVIATION 3.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
1 Participants5 Participants4 Participants
Race (NIH/OMB)
Black or African American
1 Participants4 Participants3 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants3 Participants2 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
4 Participants16 Participants12 Participants
Region of Enrollment
United States
7 Participants29 Participants22 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
7 Participants29 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 370 / 14
other
Total, other adverse events
0 / 370 / 14
serious
Total, serious adverse events
0 / 370 / 14

Outcome results

Primary

Myocardial Perfusion Reserve

Measurement of myocardial blood flow has only been analyzed at baseline at this time. Intravenous 13NH3 will be used as the flow tracer and serial imaging with PET will be performed. Measurements will be performed at baseline, and after pharmacologic stress with dipyridamole. Myocardial blood flow at rest and following dipyridamole infusion will be expressed as ml flow/100 g/min. The myocardial perfusion reserve will be calculated as the ratio of the myocardial blood flow during stress (e.g. after dipyridamole) and the myocardial blood flow at rest. Commercially available software (Emory tool box) will be used to quantitatively analyze PET myocardial perfusion images.

Time frame: baseline and 1 year

Population: Patients undergoing angiography for detection of coronary artery disease.

ArmMeasureGroupValue (MEAN)Dispersion
Exercise Intervention GroupMyocardial Perfusion ReserveBaseline2.76 RatioStandard Deviation 0.61
Exercise Intervention GroupMyocardial Perfusion Reserve1-year2.82 RatioStandard Deviation 0.56
PCI Group (Usual Care)Myocardial Perfusion ReserveBaseline2.47 RatioStandard Deviation 0.48
PCI Group (Usual Care)Myocardial Perfusion Reserve1-year2.52 RatioStandard Deviation 0.43
Secondary

Peak VO2

Peak VO2 will be determined at baseline and 1 year on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses.

Time frame: baseline and after 1 year

Population: Subjects undergoing angiography for detection of coronary artery disease.

ArmMeasureGroupValue (MEAN)Dispersion
Exercise Intervention GroupPeak VO21 Year22.4 ml/kg/minStandard Deviation 4.1
Exercise Intervention GroupPeak VO2Baseline20.21 ml/kg/minStandard Deviation 3.76
PCI Group (Usual Care)Peak VO21 Year18.91 ml/kg/minStandard Deviation 5.92
PCI Group (Usual Care)Peak VO2Baseline19.85 ml/kg/minStandard Deviation 6.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026